Evolent Capital Surpluse vs Net Invested Capital Analysis
EVH Stock | USD 23.07 0.24 1.03% |
Evolent Health financial indicator trend analysis is much more than just examining Evolent Health latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Evolent Health is a good investment. Please check the relationship between Evolent Health Capital Surpluse and its Net Invested Capital accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolent Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.
Capital Surpluse vs Net Invested Capital
Capital Surpluse vs Net Invested Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Evolent Health Capital Surpluse account and Net Invested Capital. At this time, the significance of the direction appears to have weak relationship.
The correlation between Evolent Health's Capital Surpluse and Net Invested Capital is 0.39. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of Evolent Health, assuming nothing else is changed. The correlation between historical values of Evolent Health's Capital Surpluse and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Evolent Health are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Capital Surpluse i.e., Evolent Health's Capital Surpluse and Net Invested Capital go up and down completely randomly.
Correlation Coefficient | 0.39 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Capital Surpluse
Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Most indicators from Evolent Health's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Evolent Health current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolent Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.As of now, Evolent Health's Enterprise Value Multiple is increasing as compared to previous years.
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 908.0M | 1.4B | 2.0B | 2.1B | Depreciation And Amortization | 60.0M | 67.2M | 123.4M | 129.6M |
Evolent Health fundamental ratios Correlations
Click cells to compare fundamentals
Evolent Health Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Evolent Health fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.5B | 1.4B | 1.4B | 1.8B | 2.7B | 2.8B | |
Other Current Liab | 129.2M | 321.5M | 330.4M | 363.4M | 610.3M | 640.8M | |
Total Current Liabilities | 192.8M | 401.8M | 445.5M | 433.4M | 674.2M | 708.0M | |
Total Stockholder Equity | 922.4M | 619.6M | 693.6M | 859.4M | 1.1B | 706.1M | |
Property Plant And Equipment Net | 157.3M | 144.0M | 131.6M | 136.9M | 90.2M | 84.7M | |
Net Debt | 267.8M | 19.3M | 14.2M | 287.9M | 452.0M | 474.6M | |
Retained Earnings | (252.0M) | (589.2M) | (626.8M) | (606.2M) | (719.2M) | (683.2M) | |
Accounts Payable | 37.5M | 32.1M | 96.1M | 57.2M | 48.2M | 48.9M | |
Cash | 101.0M | 340.5M | 266.3M | 188.2M | 192.8M | 176.4M | |
Non Current Assets Total | 1.3B | 824.1M | 895.5M | 1.3B | 2.0B | 2.1B | |
Non Currrent Assets Other | 8.3M | 7.3M | 13.0M | 32.3M | 20.9M | 21.9M | |
Other Assets | 92.0M | 186.5M | 52.4M | 32.3M | 33.0M | 60.4M | |
Cash And Short Term Investments | 101.0M | 340.5M | 266.3M | 188.2M | 192.8M | 196.3M | |
Net Receivables | 77.4M | 126.3M | 130.6M | 254.7M | 446.7M | 469.1M | |
Common Stock Shares Outstanding | 82.4M | 84.9M | 86.1M | 93.7M | 111.3M | 70.4M | |
Liabilities And Stockholders Equity | 1.5B | 1.4B | 1.4B | 1.8B | 2.7B | 2.8B | |
Other Current Assets | 200.5M | 524.4M | 435.3M | 451.1M | 30.3M | 28.8M | |
Other Stockholder Equity | 1.2B | 1.2B | 1.3B | 1.5B | 1.6B | 1.7B | |
Total Liab | 569.0M | 750.6M | 725.8M | 957.9M | 1.6B | 1.7B | |
Total Current Assets | 228.8M | 546.1M | 524.0M | 478.1M | 683.7M | 354.3M | |
Intangible Assets | 308.5M | 268.1M | 279.8M | 442.8M | 752.0M | 789.6M | |
Other Liab | 13.7M | 455.2M | 6.9M | 55.4M | 63.8M | 71.7M | |
Current Deferred Revenue | 19.8M | 14.3M | 11.9M | 5.8M | 6.0M | 5.7M | |
Short Term Investments | 1.8M | 3.9M | 75.7M | 14.5M | 13.8M | 25.7M | |
Non Current Liabilities Total | 376.2M | 348.8M | 280.3M | 524.4M | 938.4M | 985.3M | |
Inventory | 78.5M | (150.1M) | (445.1M) | (308.2M) | (415.9M) | 1.05 | |
Property Plant And Equipment Gross | 157.3M | 144.0M | 250.7M | 287.4M | 248.7M | 139.8M | |
Accumulated Other Comprehensive Income | (234K) | (278K) | (362K) | (1.2M) | (1.3M) | (1.3M) | |
Short Term Debt | 6.3M | 33.9M | 7.1M | 7.1M | 9.7M | 9.3M | |
Property Plant Equipment | 85.2M | 86.2M | 81.4M | 87.9M | 101.1M | 60.1M | |
Net Tangible Assets | 41.8M | (3.2M) | (12.4M) | (306.1M) | (275.5M) | (261.8M) | |
Long Term Debt | 293.7M | 263.3M | 215.7M | 413.0M | 597.0M | 626.9M | |
Good Will | 572.1M | 354.7M | 426.3M | 722.8M | 1.1B | 707.6M | |
Common Stock Total Equity | 846K | 859K | 908K | 1.0M | 1.2M | 791.4K | |
Deferred Long Term Liab | 1.9M | 728K | 1.4M | 4.7M | 4.3M | 4.1M | |
Long Term Investments | 139.4M | 17.4M | 5.5M | 4.5M | 4.9M | 4.7M | |
Common Stock | 846K | 859K | 908K | 1.0M | 1.2M | 839.2K | |
Retained Earnings Total Equity | (252.0M) | (589.2M) | (626.8M) | (606.2M) | (545.5M) | (518.3M) |
Currently Active Assets on Macroaxis
When determining whether Evolent Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evolent Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evolent Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evolent Health Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolent Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Evolent Stock analysis
When running Evolent Health's price analysis, check to measure Evolent Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolent Health is operating at the current time. Most of Evolent Health's value examination focuses on studying past and present price action to predict the probability of Evolent Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolent Health's price. Additionally, you may evaluate how the addition of Evolent Health to your portfolios can decrease your overall portfolio volatility.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Equity Valuation Check real value of public entities based on technical and fundamental data |
Is Evolent Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolent Health. If investors know Evolent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolent Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.26) | Revenue Per Share 19.283 | Quarterly Revenue Growth 0.496 | Return On Assets 0.0062 | Return On Equity (0.09) |
The market value of Evolent Health is measured differently than its book value, which is the value of Evolent that is recorded on the company's balance sheet. Investors also form their own opinion of Evolent Health's value that differs from its market value or its book value, called intrinsic value, which is Evolent Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolent Health's market value can be influenced by many factors that don't directly affect Evolent Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evolent Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evolent Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolent Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.